Monday, July 10, 2006

Study compares breast-cancer drugs

Mayo Clinic: Can you provide an update on the recent breast cancer prevention research that was in the news? - Thornhill, Ontario, Canada. Answer (from Dr. Sandhya Pruthi, Breast Diagnostic Clinic, Mayo Clinic, Rochester, Minn.): You are probably referring to the National Cancer Institute's Study of Tamoxifen and Raloxifene (STAR) Trial. The initial results were released in April 2006 and are important for anyone who is at high risk of developing breast cancer. This four-year study, with nearly 20,000 women participating, compared the effectiveness of drugs tamoxifen (Nolvadex) and raloxifene (Evista) in reducing breast cancer for postmenopausal women at increased risk of the disease. Results from a landmark 1998 study had already shown that tamoxifen reduced the risk of invasive breast cancer in premenopausal and postmenopausal women by about 50 percent. STAR researchers found that raloxifene, a drug used to treat osteoporosis, was just as effective as tamoxifen in reducing the risk of developing invasive breast cancer in postmenopausal women. Both tamoxifen and raloxifene are selective estrogen receptor modulators and work by blocking estrogen receptors found in the breast from binding to estrogen. Estrogen stimulates breast tissue and cell proliferation and has been implicated in the development of breast cancer. --Click the title of this post to read the full article from its source--


Post a Comment

<< Home

/* WebRing Code */